Swiss Life Asset Management’s Apollo Global Management APO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.5M Buy
97,221
+36,326
+60% +$4.57M 0.05% 287
2026
Q1
$6.78M Buy
60,895
+11,700
+24% +$1.45M 0.03% 355
2025
Q4
$7.12M Buy
49,195
+994
+2% +$132K 0.04% 342
2025
Q3
$6.42M Buy
48,201
+9,936
+26% +$1.41M 0.03% 352
2025
Q2
$5.43M Buy
38,265
+6,361
+20% +$844K 0.03% 357
2025
Q1
$4.37M Buy
31,904
+2,877
+10% +$442K 0.03% 364
2024
Q4
$4.79M Buy
29,027
+9,978
+52% +$1.58M 0.04% 318
2024
Q3
$2.38M Sell
19,049
-3,875
-17% -$447K 0.03% 352
2024
Q2
$2.71M Sell
22,924
-29,051
-56% -$3.3M 0.03% 339
2024
Q1
$5.84M Buy
51,975
+22,348
+75% +$2.36M 0.08% 208
2023
Q4
$2.77M Sell
29,627
-40,813
-58% -$3.6M 0.03% 398
2023
Q3
$6.32M Buy
+70,440
New +$5.92M 0.1% 246
2022
Q1
Sell
-20,369
Closed -$1.48M 568
2021
Q4
$1.48M Buy
+20,369
New +$1.47M 0.02% 446

Other funds holding APO

Swiss Life Asset Management's APO Position: Q2 2026 in Review

Swiss Life Asset Management increased its Apollo Global Management (APO) stake by 60% in Q2 2026, buying an estimated $4.57M and bringing the position to 97,221 shares worth $11.5M. The position accounts for 0.05% of the portfolio, ranked #287.

Swiss Life Asset Management first reported a position in APO in Q4 2021 and has held it in 13 quarters since. 822 funds tracked by Wall St. Rank hold APO as of Q2 2026.

  • Swiss Life Asset Management held 97,221 shares of Apollo Global Management worth $11.5M as of Q2 2026.
  • Swiss Life Asset Management bought 36,326 Apollo Global Management shares in Q2 2026, an estimated $4.57M.
  • Apollo Global Management made up 0.05% of Swiss Life Asset Management's portfolio in Q2 2026, its #287 holding.
  • Swiss Life Asset Management first reported a position in Apollo Global Management in Q4 2021 and has held it in 13 quarters since.
  • 822 funds tracked by Wall St. Rank held Apollo Global Management as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.